Safety of Therapeutic Oligonucleotides

April 1st, 2020|Categories: Past Webinars|

Presenter: Patrik Andersson (AstraZeneca) Date: May 13, 2020 Description: Successful therapeutics need to be efficacious and safe. Although oligonucleotide therapeutics act via unique mechanisms, they follow the same principles for safety assessment as other modalities. This webinar will give an overview of these principles and what ...

Chimeric siRNAs with chemically modified pentofuranose and hexopyranose nucleotides: altritol-nucleotide (ANA) containing GalNAc-siRNA conjugates: in vitro and in vivo RNAi activity and resistance to 5′-exonuclease

March 31st, 2020|Categories: Ago/siRNA/saRNA|

Kumar P, Degaonkar R, Guenther DC, Abramov M, Schepers G, Capobianco M, Jiang Y, Harp J, Kaittanis C, Janas MM, Castoreno A, Zlatev I, Schlegel MK, Herdewijn P, Egli M, Manoharan M. Nucleic Acids Res. 2020 Mar 14. PubMed

Go to Top